SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Feldman HA, Longcope C, Derby CA et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002; 87: 58998
  • 2
    Yassin A, Saad F. Treatment of sexual dysfunction of hypogonadal patients with long acting testosterone undecanoate (Nebido®). World J Urol 2006; 24: 63944
  • 3
    Moon DG, Park MG, Lee SW et al. The efficacy and safety of testosterone undecanoate (nebido®) in testosterone deficiency syndrome in korean: a multicenter prospective study. J Sex Med 2010; 7: 225360
  • 4
    Heinemann LAJ, Zimmermann T, Vermeulen A, Thiel C. A new aging male's symptoms' (AMS) rating scale. Aging Male 1999; 2: 10514
  • 5
    Badia X, Herdman M. The importance of health-related quality-of-life data in determining the value of drug therapy. Clin Ther 2001; 23: 16875
  • 6
    Heinemann LAJ, Saad F, Thiele K, Wood-Dauphinee S. The Aging Males' Symptoms (AMS) rating scale. Cultural and linguistic validation into English. Aging Male 2001; 3: 1422
  • 7
    Heinemann LAJ, Saad F, Pöllänen P. Measurement of quality of life specific for aging males. Schneider HPG eds, In Hormone Replacement Therapy and Quality of Life, London, New York, Washington: Parthenon Publishing Group, 2002: 6383
  • 8
    Heinemann LA, Saad F, Heinemann K, Thai DM. Can results of the AMS scale predict those of screening scales for androgen deficiency? Aging Male 2004; 7: 2118
  • 9
    Morley JE, Perry HM, Kevorkian RT, Patrick P. Comparison of screening questionnaires for the diagnosis of hypogonadism. Maturitas 2006; 53: 4249
  • 10
    Kratzik CW, Reiter WJ, Riedl AM et al. Hormone profiles, body Maß Index and aging male symptoms – results of the androx Vienna municipality study. Aging Male 2004; 7: 18896
  • 11
    Itoh N, Hisasue S, Kato R et al. Comparison of Morley's ADAM questionnaire and Heinemann's Aging Male Symptoms (AMS) rating scale to screen andropause symptoms in Japanese males. Aging Male 2004; 7: 49
  • 12
    Soh J, Ishida Y, Naito Y et al. Correlations of AMS score, depression score and hormonal levels with the manifestation of partial androgen decline in the aging male (PADAM). Aging Male 2004; 7: 83
  • 13
    Jankowska EJ, Szklarska A, Lopuszanska M, Medras M. Hormonal determinants of andropausal symptoms in Polish men. Aging Male 2004; 7: 21
  • 14
    Heinemann LA, Moore C, Dinger JC, Stoehr D. Sensitivity as outcome measure of androgen replacement: the AMS scale. Health Qual Life Outcomes 2006; 4: 23
  • 15
    Legros JJ, Meuleman EJ, Elbers JM, Geurts TB, Kaspers MJ, Bouloux PM. Study 43203 Investigators. Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. Eur J Endocrinol 2009; 160: 82131
  • 16
    Moore C, Huebler D, Zimmermann T, Heinemann LAJ, Saad F, Thai DM. The aging males' symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol 2004; 46: 807
  • 17
    Morgentaler A, Dobs AS, Kaufman JM et al. Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study. J Urol 2008; 180: 230713
  • 18
    Schubert M, Minnemann T, Hubler D et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 2004; 89: 542934
  • 19
    Tan HM, Khoo EM, Ng CJ, Low WY, Yap PK, Tan WS. The Aging Males' Symptoms' Scale (AMS) – a general screening instrument for aging males' health problem? Eur Urol 2007; (Suppl) 6: 107
  • 20
    Sararaks S, Azman AB, Low LL et al. Validity and reliability of the SF-36: the Malaysian context. Med J Malaysia 2005; 60: 16379
  • 21
    Giltay EJ, Tishova YA, Mskhalaya GJ, Gooren LJG, Saad F, Kalinchenko SY. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med 2010; 7: 257282
  • 22
    Aversa A, Bruzziches R, Francomano D, Spera G, Lenzi A. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. J Endocrinol Invest 2010; 33: 77683
  • 23
    Permpongkosol S, Tantirangsee N, Ratana-olarn K. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints. J Sex Med 2010; 7: 376574
  • 24
    Basaria S, Coviello AD, Travison TG et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 10922